China Life Insurance announces governance changes and a major investment partnership, highlighting a strategic pivot towards long-term, related-party investments amidst evolving regulatory landscapes in Asia's insurance sector.
Deutsche Bank and its asset manager DWS are in preliminary talks to acquire a significant minority stake in Fosun-owned Frankfurter Leben, signaling a strategic reversal a decade after exiting the sector.
A Beijing court has sentenced ex-Justice Minister Tang Yijun to life imprisonment on bribery charges, state media reported Monday, marking one of the highest-profile convictions in China's ongoing anti-corruption campaign.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
A new report from crypto market maker Wintermute Ventures forecasts a seismic shift, arguing that blockchain-based prediction markets will begin displacing traditional insurance by making hyper-specific risks tradable. The firm outlines a future where decentralized infrastructure becomes the new clearing layer for a programmable global economy.
Hong Kong apparel giant Crystal International is investing in a high-tech logistics center in China, aiming to slash fabric transfer times by 75% and power operations with solar energy as part of its broader smart manufacturing push.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
French reinsurer SCOR has expanded its underwriting capacity for Baobab Insurance's cyber policies in Germany and Austria, now covering companies with annual revenues up to €1 billion, marking a strategic push into Europe's industrial cyber risk market.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
A private gauge of China's manufacturing activity edged higher in January, defying expectations of a slowdown, as export-oriented firms outperformed. The reading contrasts with weaker official data, highlighting a two-speed industrial sector amid persistent domestic headwinds.
The global apparel manufacturer is launching a state-of-the-art logistics center in China, featuring a fully automated closed-loop material flow system. The facility aims to slash fabric transfer times by up to 75%, optimize inventory, and advance the company's 2030 sustainability goals through solar power and waste-reduction technologies.
Finnish technology leader Valmet introduces a new line of bio-based press roll covers, backed by specific lifecycle assessment data, to help paper manufacturers reduce fossil resource dependence and track emissions.
The Hartford Financial Services Group reported stellar full-year 2025 results, with core earnings reaching $3.8 billion and a return on equity of 19.4%. Strong performance across Business, Personal, and Employee Benefits insurance segments, coupled with strategic investments in AI and digital capabilities, positions the insurer for sustained market leadership.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Equity Lifestyle Properties (ELS) reported solid 2025 results with NOI and FFO growth, driven by its core manufactured housing communities. While forecasting further growth for 2026, management acknowledged ongoing fluctuations in its seasonal RV business and provided detailed guidance.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
NVIDIA's CEO Jensen Huang indicates that Chinese regulatory approval for the sale of its flagship H200 AI chip is still pending, amid high demand from major tech firms and ongoing U.S.-China tech tensions.
